Epix to cut work force, narrow research focus

10/23/2008 | AuntMinnie.com (free registration)

Epix Pharmaceuticals has announced plans to slash its work force by 23% and reduce its research and development focus in order to cut costs. The contrast-agent developer said it will concentrate on developing PRX-03140 for Alzheimer's disease and PRX-08066 for chronic obstructive pulmonary disease but will continue plans to market its Vasovist MRI contrast agent.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care